Targeted Therapy for Cancer: Biomarkers, Matched Drugs and Treatment Access
If your molecular report shows a genetic alteration — or a clinic has offered you a "targeted" drug — the real question is not "what does this mutation mean?" but "is there an effective, evidence-supported, and actually accessible treatment for my exact cancer?"
This page walks you from a test result to a real treatment decision. It separates what the alteration is, what level of evidence exists for it in your cancer type, what regulatory approval means in each country, and what to verify before committing to a treatment pathway.
Finding a Mutation Is Not Finding a Treatment
Common belief: "If my report shows a mutation, there must be a drug for it."
What the evidence shows: Many molecular alterations have no approved or effective targeted drug. Even when a drug exists, its benefit depends on the exact alteration (not just the gene name), the cancer type, and the line of therapy. For example, "KRAS" alone does not identify a usable drug — the specific KRAS variant matters, and only some variants have approved treatments in specific cancers.
Remember this: A mutation is a finding. A treatment is a decision. They are not the same step.
This page is NOT for patients seeking a treatment recommendation, a guarantee of access, or an interpretation of their own molecular report. It IS for patients, families, caregivers, and referring physicians who want a clear, honest framework for understanding what a molecular finding means, what level of evidence exists, what regulatory approval actually covers, and what to verify before pursuing a targeted therapy.
- Does my exact alteration — not just the gene name — have evidence of benefit in my cancer type?
- Is there a matched drug approved for my cancer and line of therapy, and in which country?
- If it is off-label or investigational, what is the trial or the supporting evidence?
- What is the expected benefit, the main risks, and the monitoring required?
- Is the drug actually accessible where I would receive it, and at what total cost?
- What should I ask the clinic before committing to travel or payment?
What Is Targeted Therapy — and What It Is Not
Targeted therapy is an established treatment approach. But the phrase covers many different drugs, targets, and evidence levels.
Three common mistakes
- Assuming a mutation means a treatment exists. Many alterations have no approved or effective drug.
- Assuming FDA approval means global access. A drug approved in one country may not be approved, reimbursed, or commercially available in another.
- Assuming more testing means more options. Broader testing only helps when the result could change the treatment decision in your cancer type.
What My Test Result Means — Alteration Types
Molecular reports describe different kinds of findings. They are not interchangeable.
Point mutation or small change
A change in the DNA sequence of a gene. Some mutations are actionable (a drug targets them); many are not. The exact variant — not just the gene name — often determines whether a drug applies.
Gene fusion / rearrangement
Two genes joined abnormally, producing a new fusion protein. Some fusions (e.g., ALK, ROS1, RET, NTRK) have approved targeted drugs in specific cancers.
Gene amplification / overexpression
Multiple copies of a gene, sometimes driving overexpression of a protein. Whether this is actionable depends on the cancer type and the drug's evidence in that setting.
Protein expression / biomarker
Measured by immunohistochemistry (e.g., HER2, PD-L1). A positive result may open a treatment pathway — but the threshold and meaning differ by cancer and drug.
Is This Target Actually Treatable? Three Evidence Levels
Not every alteration has the same strength of evidence — even when the gene name is the same.
Target has a clinically validated treatment in this cancer
The alteration is matched to a drug with published clinical evidence — usually a phase 3 trial or a regulatory approval — in this exact cancer type. Examples include certain EGFR mutations in NSCLC, or BCR-ABL fusions in CML. The matched treatment is usually standard-of-care.
Target has evidence in another cancer, or early-phase data
The drug may be approved for a different cancer with the same alteration, or supported by phase 1–2 data. Off-label use may be considered by the treating team, but evidence is less mature and outcomes may differ. Basket trials sometimes inform this tier.
Target is a research hypothesis, not a treatment decision
No published clinical evidence supports a matched treatment in this cancer. The alteration may be biologically interesting, but it should not drive treatment outside a clinical trial. Frameworks like ESCAT help classify evidence tiers — but the final decision belongs to the treating oncologist.
Drug–Target Reference Table (Illustrative)
This table is a starting point, not a formulary. Approval status is per country and changes frequently. Verify every row on the regulator's own database before making any decision.
| Molecular target | Cancer type | Alteration required | Matched treatment (example) | Evidence in this cancer | Regulatory status | Access pathway | Last verified |
|---|---|---|---|---|---|---|---|
| EGFR | Non-small cell lung cancer | Specific activating mutations (e.g., exon 19 deletion, L858R) | Osimertinib and other EGFR TKIs | Strong (phase 3, standard of care) | FDA EMA NMPA | Standard of care | 2026-10 |
| ALK | Non-small cell lung cancer | ALK fusion / rearrangement | Alectinib, lorlatinib, others | Strong (phase 3, standard of care) | FDA EMA NMPA | Standard of care | 2026-10 |
| HER2 | Breast cancer, gastric cancer, others | Amplification, overexpression, or activating mutation (varies by cancer) | Trastuzumab, T-DXd, others | Strong in defined settings; ADC options evolving | FDA EMA NMPA | Standard of care in approved settings | 2026-10 |
| BRAF | Melanoma | BRAF V600E/K mutation | Dabrafenib + trametinib, others | Strong (phase 3) | FDA EMA NMPA | Standard of care | 2026-10 |
| BRAF | Colorectal cancer | BRAF V600E mutation | Encorafenib + cetuximab (specific setting) | Limited-to-moderate; combination required | FDA EMA | Approved in specific setting | 2026-10 |
| KRAS | NSCLC | KRAS G12C specifically (not all KRAS variants) | Sotorasib, adagrasib | Moderate; second-line setting in approved regions | FDA EMA | Approved in specific setting | 2026-10 |
| NTRK | Tumor-agnostic (multiple cancers) | NTRK fusion | Larotrectinib, entrectinib | Strong for NTRK-fusion-positive solid tumors | FDA EMA | Approved (tumor-agnostic) | 2026-10 |
| BRCA1/2 | Ovarian, breast, prostate, pancreatic | Germline or somatic pathogenic variant | PARP inhibitors (olaparib, others) | Strong in defined settings | FDA EMA NMPA | Standard of care in approved settings | 2026-10 |
| Other targets | Various | Varies by target and cancer | See NCI / FDA / ESMO sources | Varies — often limited or investigational | Varies | Varies — often clinical trial only | 2026-10 |
When the Drug Is Not Available Where You Live
Regulatory approval, actual availability, and access via a clinical trial are different things.
Approval is not the same as access
- Regulatory approval means a regulator has reviewed the drug for a specific indication. It does not mean the drug is available, reimbursed, or commercially supplied everywhere.
- Off-label use means a prescriber uses an approved drug outside its approved indication. Evidence and reimbursement vary widely.
- Clinical trial access depends on eligibility criteria, recruitment status, and whether the site accepts international patients.
| Clinical Need | Required Capability | Potential Access Pathways |
|---|---|---|
| Need to know whether my alteration is actionable | Report reviewed by a molecular tumor board or oncologist with genomics experience | Local oncology review → targeted testing if needed → evidence classification |
| Need an approved targeted drug in my country | Drug approved and available for my exact cancer and line | Verify on regulator database → confirm hospital supply → plan monitoring |
| Drug is approved elsewhere but not at home | Named-patient / compassionate use program, or cross-border access | Ask the manufacturer → check national early-access programs → discuss risk/benefit with oncologist |
| Need an investigational targeted therapy | Trial site with active recruitment and matching eligibility | ClinicalTrials.gov / ChiCTR / EU CTR search → contact site → confirm eligibility |
| Need continuity after returning home | Written follow-up plan and a named contact at the treating center | Request in writing before travel; share with your local oncologist |
Molecular Finding → Treatment Pathway
A checklist, not a medical interpretation. It helps you organize the questions to ask your oncologist and any treating center.
What to organize before evaluating any targeted therapy option
Collect each field from your molecular report and from any clinic that has offered a targeted therapy. If a field is empty, that is the first thing to request.
Not just the gene name — the specific variant, fusion, or amplification (e.g., "EGFR exon 19 deletion", not "EGFR").
The exact cancer subtype, stage, and prior treatments — evidence depends on these.
Generic and brand name of the drug, and whether it is approved, off-label, or investigational.
Strong (phase 3 / approval in this cancer), limited (other cancer, phase 1–2), or insufficient (hypothesis only).
Where the drug is approved for my exact indication — FDA, EMA, NMPA, or other — and as of what date.
What a complete evaluation should answer
- Confirmed: the alteration is actionable in this cancer type, and a matched drug exists with appropriate evidence.
- Still unclear: the exact approval status in the country where treatment would occur, and whether the center can supply the drug and monitor its risks.
- Documentation to request: the full molecular report, the regulator approval letter (or trial protocol), the written treatment plan including monitoring, and the total cost breakdown.
Frequently Asked Questions
Does finding a mutation mean there is a drug for it?
No. Many mutations have no approved or effective targeted drug. Even when a drug exists for the same gene, its benefit depends on the exact variant, the cancer type, and the line of therapy. For example, KRAS G12C has specific drugs in specific cancers — but "KRAS" alone does not identify a usable treatment.
What is the difference between a mutation, a fusion, and an amplification?
A mutation is a change in the DNA sequence. A fusion is two genes joined abnormally, producing a new protein. An amplification means multiple copies of a gene, sometimes driving overexpression. Each type has its own treatment landscape, and the same gene can behave differently depending on which alteration is present.
Is a targeted drug approved in the US also available in my country?
Not necessarily. FDA, EMA, and NMPA approvals are independent. A drug approved in one jurisdiction may not be approved, reimbursed, or commercially available in another. Always verify on the regulator's database for the country where treatment is proposed.
Can I use a targeted drug off-label based on my molecular result?
Sometimes — but off-label use depends on the evidence, the prescriber, the institution, and the country's regulations. Off-label does not mean "experimental" or "unsafe" automatically, but the evidence is usually weaker than for an approved indication. Discuss the specific evidence with your oncologist.
Do I need more testing — for example, a liquid biopsy?
Possibly, but only if the result could change a treatment decision in your cancer type. A negative blood test does not always rule out a tumor alteration, and broader testing does not always produce more options. Your oncologist can advise whether re-biopsy, additional tissue testing, or a liquid biopsy is warranted.
Should I travel abroad for a targeted therapy?
Travel is worth considering only when the destination adds a specific, verifiable treatment option — not as a general strategy. Before committing, confirm the drug's approval status for your exact indication in that country, the center's ability to manage side effects, the total cost, and the post-discharge follow-up plan. See our country access guides for structured comparison.
Does CancerCareE recommend a specific targeted therapy or center?
No. CancerCareE does not recommend treatments, rank centers, or guarantee access. It provides referenced information and, with your consent, can introduce your contact details to partner institutions. See our Financial Transparency page.
Want Help Organizing Your Molecular Report and Options?
With your consent, CancerCareE can introduce your name, phone number, and preferred destination country to partner institutions. We do not ask for your medical records on this form, and we do not diagnose, recommend treatments, or promise eligibility, outcomes, or access to any institution.
Continue Exploring
Molecular Testing
What NGS, IHC, and liquid biopsy can — and cannot — tell you.
Immunotherapy
Checkpoint inhibitors and the broader immunotherapy landscape.
Antibody-Drug Conjugates
Targeted delivery of chemotherapy payloads.
Clinical Trials
How to read a trial and evaluate eligibility.
Access by Country
Pathways across destinations.
How We Are Funded
Our business model and conflict-of-interest policy.
Sources & Review
- National Cancer Institute — NCI Dictionary of Cancer Terms and targeted therapy patient information. cancer.gov
- U.S. Food & Drug Administration — Drugs@FDA (approval letters, companion diagnostics, indications). accessdata.fda.gov
- European Medicines Agency — Medicines (EPAR). ema.europa.eu
- National Medical Products Administration (China) — drug approvals. nmpa.gov.cn
- ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) — evidence tier framework for molecular alterations.
- NCCN Guidelines and ESMO Clinical Practice Guidelines — targeted therapy recommendations by cancer type.
- ClinicalTrials.gov and ChiCTR — trial registries (recruitment status and eligibility).
- CancerCareE editorial policy — evidence-based overview with review by board-certified oncologists. Last reviewed: October 2026.